-
Innovent Biologics’ Tafolecimab Shows Strong LDL-C Reduction in Phase III Study
•
China-based Innovent Biologics, Inc. (HKG: 1801) announced the results of the Phase III CREDIT-1 study for tafolecimab (IBI306), a recombinant fully human anti-PCSK-9 monoclonal antibody (mAb), in Chinese patients with non-familial hypercholesterolemia (non-FH). The findings were presented at the American Heart Association (AHA) Scientific Sessions 2022 as an e-poster (VP173).…
-
Allergan Aesthetics Partners with Sinopharm at CIIE for Aesthetic Medicine
•
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced a partnership with Sinopharm Group Co., Ltd’s global procurement and supply chain service center at the 5th China International Import Expo (CIIE). The collaboration aims to deepen their partnership in several key areas, including product supply security, new product launches, and…
-
Honeywell Partners with Anruite for Smart Manufacturing in China
•
US major Honeywell (NASDAQ: HON) has announced a partnership with China-based Tonghua Anruite Biopharmaceutical Co., Ltd at the 5th China International Import Expo (CIIE). The collaboration aims to delve into smart manufacturing and digital transformation, focusing on building a digital innovation system to enhance the smart upgrade of pharmaceutical industry…
-
Boehringer Ingelheim Launches Rehabilitation Center in Chengdu at CIIE
•
The 5th China International Import Expo (CIIE) saw the unveiling of Boehringer Ingelheim’s Consanas (Chengdu) Rehabilitation Center, a joint effort between the German major and the Chengdu Wenjiang local government. This marks a significant step in enhancing stroke rehabilitation medicine in China. Center ProfileThe Consanas (Chengdu) Rehabilitation Center, focused on…
-
Fosun Pharma Partners with Soong Ching Ling Foundation for Women and Children’s Health
•
The 5th China International Import Expo (CIIE) saw Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announce a partnership with the Shanghai Soong Ching Ling Foundation. The collaboration aims to carry out medical and health public welfare activities for women and children, with Xishuangbanna of Yunnan province as the primary…
-
Jumpcan Partners with Newsoara for PDE4 and Protease Inhibitors in China
•
China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a partnership with compatriot firm Newsoara BioPharma Co., Ltd to develop and commercialize two target products in mainland China. The collaboration involves a PDE4 inhibitor (target product one) and a protease inhibitor (target product two). Jumpcan will pay RMB 180 million (USD 24.8…
-
Novo Nordisk to Invest RMB 400M in Shanghai at CIIE
•
Novo Nordisk (NYSE: NVO) has announced at the 5th China International Import Expo (CIIE) an investment of RMB 400 million (USD 55.2 million) to establish an investment unit in Shanghai. The new unit is designed to maintain ownership of its manufacturing, trade, research and development (R&D), and other business operations…
-
Jiangsu Yahong Initiates Phase III Study for Hexvix in Bladder Cancer Detection
•
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the enrollment of the first subject in a prospective, subject-controlled, multi-center Phase III clinical study. The study aims to assess the additional detection rate and safety of Hexvix, a bladder cancer diagnosis and postoperative detection product,…
-
Betta Pharmaceuticals’ BPI-452080 Accepted for Review by NMPA
•
China’s Betta Pharmaceuticals (SHE: 300558) has announced that a clinical trial filing for its Category 1 drug candidate BPI-452080 has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step forward in the development of the drug, which is designed to treat advanced solid…
-
Qilu Regor’s RGT-264 Phosphate Tablets Approved for Phase I Study
•
China-based biotech Qilu Regor Therapeutics Inc has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase I study. The study will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of its RGT-264 phosphate tablets in patients with advanced solid tumors. RGT-264 ProfileRGT-264 is a…
-
Hainan Free Trade Port to Simplify Drug Import Procedures
•
The “Provisions on Facilitation of Drug Import in Hainan Free Trade Port,” released in September this year, will take effect as of December 1, 2022. These new regulations aim to streamline the import process for pharmaceuticals, enhancing efficiency and reducing administrative burdens. Regulatory ChangesThe Provisions specify that enterprises importing drugs…
-
Reforgene Medicine RM-001 Thalassemia Gene Editing
•
China-based Guangzhou Reforgene Medicine Co., Ltd’s in-house developed β-thalassemia gene editing drug RM-001 (HBG gene modified autologous CD34+ hematopoietic stem cell injection) has obtained tacit clinical trial approval from the National Medical Products Administration (NMPA). This marks a significant milestone for the first thalassemia gene editing novel drug program in…
-
Walvax Biotech Launches Phase IIIb Trial for mRNA COVID-19 Vaccine
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the initiation of a Phase IIIb clinical study with ethics approval. The study is designed to assess the immunogenicity and safety of its “novel coronavirus variant mRNA vaccine” (S protein chimera) in individuals aged 18 and above who have completed three…
-
Guangdong Zhongsheng Initiates Phase III Study for RAY1216 in COVID-19
•
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the initiation of a randomized, double-blind, placebo-controlled Phase III study with ethics approval for its RAY1216 in mild and common SARS-CoV-2 infection. The study is expected to enroll 1,070 patients with mild and common COVID-19 infection, using placebo as the…
-
Bloomage Biotech CEO Investigated Over Discounted Share Sales
•
The chairwoman of Chinese medical aesthetics player Bloomage Biotech Corp., Ltd (SHA: 688363), Ms. Zhao Yan, is facing an investigation from stock exchange authorities following whistleblower accusations that she pressured employees into selling their shares in the company at a discount. The China Securities Regulatory Commission (CSRC) and Shandong Securities…
-
Ascentage Pharma Announces Clinical Advances for Olverembatinib at ASH
•
Suzhou-based Ascentage Pharma (HKG: 6855) announced the latest clinical development of its olverembatinib (HQP1351), a third-generation BCR-ABL-targeted tyrosine kinase inhibitor (TKI), Bcl-2 inhibitor lisaftoclax (APG-2575), and MDM2-p53 inhibitor alrizomadlin (APG115) at the 64th American Society of Hematology (ASH) annual meeting this year. Olverembatinib in CML and Ph+ALLOlverembatinib can overcome drug…
-
Abbisko Enrolls First Patient in Phase II Study for ABSK091 in Urothelial Carcinoma
•
China-based Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the enrollment of the first patient in a Phase II clinical study for its investigational pan-FGFR inhibitor ABSK091, in combination with BeiGene Ltd’s anti-PD-1 antibody tislelizumab, for the treatment of urothelial carcinoma (UC). This marks the first clinical combination trial of…
-
Blue Shield Pharma’s LD013 CAR-T Therapy Approved for Clinical Trials
•
China-based Blue Shield Biotech’s in-house developed LD013, an autologous chimeric antigen receptor (CAR)-T cell therapy, has obtained clinical trial approval from the National Medical Products Administration (NMPA). The intended indication is recurrent refractory ovarian cancer, a condition that poses significant challenges in treatment and management. Mesothelin as a TargetMesothelin (MSLN)…
